← FDA DRUG APPROVALS

FDA ANDA · ANDA207217

NYSTATIN AND TRIAMCINOLONE ACETONIDE

Sponsor: EPIC PHARMA LLC

APPLICATION
ANDA207217
TYPE
ANDA
ORIGINAL APPROVAL
2017-08-04
LATEST ACTION
2017-08-04
ROUTE
TOPICAL
DOSAGE FORM
OINTMENT
MARKETING STATUS
Prescription

Products

NYSTATIN AND TRIAMCINOLONE ACETONIDEPrescription
NYSTATIN 100,000 UNITS/GM, TRIAMCINOLONE ACETONIDE 0.1% · OINTMENT · TOPICAL

Approval history

2017-08-04UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →